Welcome to our dedicated page for 20/20 Biolabs SEC filings (Ticker: AIDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on 20/20 Biolabs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into 20/20 Biolabs's regulatory disclosures and financial reporting.
20/20 Biolabs, Inc. granted Chief Financial Officer Alan B. Bergman a stock option covering 100,000 shares of common stock. The option has an exercise price of $1.88 per share and expires on April 2, 2036. This is a compensation-related award, not an open-market purchase.
According to the vesting terms, 25,000 shares under the option vest on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the next 36 months, as long as he continues to serve the company.
20/20 Biolabs, Inc. Chief Operating Officer Zhou Jiming received a grant of stock options covering 150,000 shares of Common Stock. The options have an exercise price of $1.88 per share, were granted on April 2, 2026, and expire on April 2, 2036. Following this grant, Zhou holds 150,000 stock options directly.
20/20 Biolabs, Inc. is registering 10,105,000 shares of common stock for resale by a single selling stockholder. The registered shares include previously issued stock, shares underlying a warrant, a secured convertible note, and series E convertible preferred stock. The company will not receive proceeds from share resales or conversions, only from any exercise of the warrant. 20/20 Biolabs develops AI-powered blood tests under the OneTest brand for multi-cancer early detection and chronic inflammation, operates a shared CLIA lab accelerator, and sells BioCheck field test kits. In 2025 it generated $2.0 million of revenue but recorded a net loss of $3.7 million and ended the year with a small stockholders’ deficit.
20/20 Biolabs, Inc. files a post-effective amendment to its Form S-1 to register 15,164,724 shares of common stock for resale by certain selling stockholders in connection with its direct listing.
The prospectus states these resales are by selling holders and the company will not receive proceeds from any sales. It notes 10,442,960 shares outstanding as of the date of this prospectus and discloses recent trading on Nasdaq under the symbol AIDX.
20/20 BioLabs, Inc. reported full year 2025 results with revenue of $2.0 million, up 17% from 2024. Gross profit rose to $0.6 million and gross margin expanded to 29.6% from 20.6%, helped by a higher mix of BioCheck and CLIAX revenue.
Operating expenses fell to $3.9 million from $6.0 million, improving the net loss to $3.7 million from $5.6 million. Cash was $1.0 million at year-end 2025, and in February 2026 the company closed a $5.0 million tranche under a preferred purchase agreement that could total up to $40 million. Management highlights a state-funded firefighter cancer screening program, deferred revenue of about $0.5 million, the launch of OneTest for Longevity and a recent Nasdaq listing as positioning the company for 2026 growth.
20/20 Biolabs, Inc. focuses on AI-powered blood tests for early detection and prevention of cancers and chronic diseases. Its main product, OneTest for Cancer, is a multi‑cancer early detection blood test run in a CAP‑accredited, CLIA‑licensed lab and positioned as an affordable “top‑of‑funnel” screen using protein tumor markers and machine learning.
The company added OneTest for Longevity in 2026 to track inflammatory biomarkers linked to chronic diseases and provide diet and lifestyle guidance using the Dietary Inflammatory Index. It also operates a Clinical Laboratory Innovation Accelerator to host third‑party lab‑developed tests and sells BioCheck field kits for suspicious powders. OneTest for Cancer generated 88% of 2025 revenue, with total shares outstanding rising to 10,442,960 as of March 30, 2026.
20/20 Biolabs, Inc. joint Schedule 13G discloses that Full Succeed International Limited is the record holder of 651,465 shares of common stock, representing 6.3% of the class based on 10,347,232 shares outstanding as of February 19, 2026. The statement is jointly filed by Full Succeed, and its directors Nengyuan Pan and Wei Lu, who share voting and dispositive power over the shares held by Full Succeed. Each individual disclaims beneficial ownership except for any pecuniary interest. The joint filing is signed and includes a Joint Filing Agreement.
20/20 Biolabs, Inc. chief executive officer Jonathan Cohen filed a Schedule 13D reporting a significant ownership stake in the company’s common stock. He beneficially owns 1,833,750 shares, including 467,350 shares he can acquire within sixty days through vested stock options.
This position represents 16.8% of the outstanding common stock, based on 10,442,438 shares outstanding as of March 3, 2026. Cohen’s holdings come from shares issued for services at the company’s formation and several stock option grants in 2000, 2023, 2024, and 2026. He states he has no current plans for corporate changes related to this stake.
20/20 Biolabs, Inc. reported that Chief Executive Officer Jonathan M. Cohen received a grant of stock options covering 352,936 shares of common stock. The options were granted at an exercise price of $0.0000 per share and are held directly.
According to the terms, these options vest in equal quarterly installments over four years, contingent on Cohen’s continued service with the company. After this grant, he holds stock options for 352,936 shares in total, aligning his compensation more closely with the company’s long-term performance.
20/20 Biolabs, Inc. ownership filing: Streeterville Capital LLC reports beneficial ownership of 543,680 shares, representing 9.99% of the company's common stock. The filing cites 5,442,249 shares outstanding as of February 18, 2026 and attributes the position to warrants and Series E convertible preferred rights subject to a contractual 9.99% ownership cap.
The report is filed by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife, who is identified as manager/sole member; voting and dispositive power is reported as sole for 543,680 shares.